Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

DSIPEpitalonIpamorelinCJC-1295 (with DAC)

Dimension	DSIP Delta Sleep-Inducing Peptide	Epitalon Epithalon	Ipamorelin	CJC-1295 (with DAC) DAC:GRF
Evidence tier	BHuman observational	CPreclinical only	CPreclinical only	CPreclinical only
Intelligence Score™	5.2/ 10 · Emerging	3.9/ 10 · Emerging	3.9/ 10 · Emerging	3.9/ 10 · Emerging
Family	Nonapeptide (sleep modulator)	Pineal tetrapeptide	Growth hormone secretagogue	GHRH analogue (long-acting)
Half-life	~7 min	Short	~2 h	~6–8 days
Typical dose	100–500 mcg pre-sleep	5–10 mg/day for 10–20 days, cyclic	200–300 mcg, 1–3× daily	1–2 mg/week
Routes	Subcutaneous, Intranasal	Subcutaneous	Subcutaneous	Subcutaneous
Tier label	Human observational	Preclinical only	Preclinical only	Preclinical only
Mechanism	Unclear; possible GABAergic and opioid modulation.	Reported telomerase activation in cell culture; pineal axis modulation.	Ghrelin (GHS-R1a) receptor agonist; pulses endogenous GH release.	GHRH receptor agonist; DAC binds albumin in vivo for extended exposure.
Reported uses	recovery-sleep	recovery-sleep	recovery-sleep	recovery-sleep
Contraindications	— Pregnancy	— Pregnancy — Active malignancy (theoretical)	— Active malignancy — Pregnancy	— Active malignancy — Pregnancy
Citations	1	1	1	1

BHuman observational

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: Pineal tetrapeptide
Half-life: Short
Typical dose: 5–10 mg/day for 10–20 days, cyclic
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: Reported telomerase activation in cell culture; pineal axis modulation.
Reported uses: recovery-sleep
Contraindications: — Pregnancy
— Active malignancy (theoretical)
Citations: 1

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: Growth hormone secretagogue
Half-life: ~2 h
Typical dose: 200–300 mcg, 1–3× daily
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: Ghrelin (GHS-R1a) receptor agonist; pulses endogenous GH release.
Reported uses: recovery-sleep
Contraindications: — Active malignancy
— Pregnancy
Citations: 1

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: GHRH analogue (long-acting)
Half-life: ~6–8 days
Typical dose: 1–2 mg/week
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: GHRH receptor agonist; DAC binds albumin in vivo for extended exposure.
Reported uses: recovery-sleep
Contraindications: — Active malignancy
— Pregnancy
Citations: 1

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.